Potentially inappropriate medications for patients with heart failure and risk of hospitalization from heart failure: A casecontrol study from Thailand

Jenghua, Kittipak; Chinwong, Surarong; Chinwong, Dujrudee; Ngamsom, Panadda; Muenpa, Roungtiva; Kanjanarat, Penkarn.
Pharm. pract. (Granada, Internet) ; 20(1): 1-10, Ene.-Mar. 2022. ilus, tab
Artículo en Inglés | IBECS (España) | ID: ibc-210390

Documentos relacionados

  1. Congestion and Use of Diuretics in Heart Failure and Cardiomyopathies: a Practical Guide.
  2. Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea.
  3. Identifying racial disparities in the management of heart failure with reduced ejection fraction.
  4. [Update on diagnostics and treatment of heart failure].
  5. Clinical Effects of Early and Short-Term Tolvaptan Administration in Patients Hospitalized for Acute Decompensated Heart Failure.
  6. Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial.
  7. Targeting Key Inflammatory Mechanisms Underlying Heart Failure: A Comprehensive Review.
  8. Management of Heart Failure in Hospitalized Patients.
  9. Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update.
  10. Heart failure: An update for nurses.